After being repeatedly jilted, this biotech was swept off its feet in a race to ASH: Inside Merck's $2.7B ArQule buyout
Over a period of more than a year, the execs at ArQule had one fling after the next with potential partners, but either got left at the deal altar or were jilted by cheap suitors. Then Merck stepped in and swept them up with a short, intense round of negotiations in the lead-up to ASH.
ArQule had plenty of disappointments to contend with along the way.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 82,100+ biopharma pros reading Endpoints daily — and it's free.